LAE002(afuresertib) is one of the only two AKT inhibitors in late-stage development for breast and prostate cancer globally.

LAE002(afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3). LAE002(afuresertib) has demonstrated several advantages compared to other AKT inhibitors, including higher efficacy, better potency, more significant tumor inhibition exposure and a better safety profile, based on public data. Capivasertib is the first approved AKT inhibitor from AstraZeneca, which FDA approved for HR+/HER2- breast cancer in November 2023.

With the promising efficacy data from our LAE002(afuresertib) Phase Ib study for HR+/HER2- breast cancer, which was presented in SABCS 2023, Laekna has initiated the Phase III pivotal study AFFIRM-205. We also continue to develop our clinical trials for the treatment of breast cancer, prostate cancer, ovarian cancer and PD-1/PD-L1 drug-resistant solid tumors to address the unmet medical needs. In several clinical trials, the combination of LAE002(afuresertib) with other therapeutics exhibits favorable efficacy results.

LAE102 is our internally discovered ActRIIA-specific monoclonal antibody, the first ActRIIA-specific antibody in clinical stage development for the treatment of obesity globally.

LAE102 has obtained IND approvals from the FDA and the CDE in relation to obesity. Laekna has commenced the Phase I clinical study of LAE102 and dosed the first subject in June 2024. In the pre-clinical models, LAE102 has been shown to increase lean mass and decrease fat mass.

Laekna targets to bring the precision therapy to overweight and obesity patients who are in need of novel treatment options for achieving quality weight control. Blocking Activin-ActRII pathway could promote skeletal muscle regeneration and decrease fat mass. In addition to LAE102, Laekna team is developing more drug candidates to maximize the value of targeting ActRII receptors. LAE103 is an ActRIIB-specific antibody and LAE123 is a dual inhibitor against ActRIIA/IIB. Both of them are our internally discovered antibodies for muscle and other disease indications in the pipeline of drug candidates.